ASH 2017 | Venetoclax combination therapy for relapsed CLL

Anna Schuh

While single agents are able to control relapsed chronic lymphocytic leukemia (CLL) well, they do not provide a cure. In this interview, Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK, discusses recent data regarding the use of combination therapy for the treatment of relapsed CLL, such as venetoclax with ibrutinib or antibody therapy. Prof. Schuh highlights the promising results of the CLARITY study (ISRCTN13751862) of ibrutinib in combination with venetoclax, which produced impressive MRD negativity rates. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Share this video